Value-based healthcare in France: A slow adoption of cost-effectiveness criteria
This new Economist Intelligence Unit (EIU) report, commissioned by Gilead Sciences, explores important questions about the French healthcare system. How is healthcare innovation assessed in France? To what extent is value for money influencing price negotiations with the pharmaceutical industry? Are national guidelines being adhered to in shaping France’s healthcare delivery?

8 Dec 2015

Key findings
- In France, the level of improvement is a key determinant rather than price in deciding how innovation is valued.
- Patient access to new drugs is highly valued and influential in how the French healthcare system is organised.
- A lack of transparency in the way in which final prices for new drugs are negotiated curbs progress of value-based healthcare in France.
- A lack of consistency in healthcare providers’ observance of official prescribing guidelines are also making it more complicated to assess the extent to which French health authorities are getting real value for money.
- Economic evaluation has been part of the reimbursement and pricing process for the most innovative medicines since 2013. However, cost-effectiveness criteria are not yet a key consideration in the process.
- French citizens' insurance contributions create high expectations in the delivery of cutting-edge treatments.
Further reading:

Value-based healthcare in the UK: A system of trial and error
This Economist Intelligence Unit (EIU) report, commissioned by Gilead Sciences, explores important questions about the UK healthcare system.

Value-based healthcare in Portugal: Necessity is the mother of invention
This paper examines how the recent economic crisis has shaped health technology assessment; the role of the hospital sector; and promising initiatives in integrated care, family health units and a new process for the re-evaluation of health technologies.

Value-based healthcare in Spain: Regional experimentation in a shared governance setting
Value-based healthcare in Spain is an Economist Intelligence Unit (EIU) report, commissioned by Gilead Sciences. It looks at health outcomes of treatment relative to cost and at the structure of Spanish healthcare delivery.

Value-based Healthcare in Germany: From free price-setting to a regulated market
This report looks at the evolution of health technology assessment and pharmaceutical pricing reform in Germany and examines the new focus on providers and health outcomes.